DALLAS, January 22, 2015 /PRNewswire/ --
RnRMarketResearch.com adds Ovarian Cancer Therapeutics in Asia-Pacific Markets to 2020 - Off-patent Chemo-regimens to Retain Dominance Despite New Launches to its store. The report provides an overview of the APAC ovarian cancer therapeutics industry.
The report "Ovarian Cancer Therapeutics in Asia-Pacific Markets to 2020 - Off-patent Chemo-regimens to Retain Dominance Despite New Launches" provides estimates of the market size for 2013, along with forecasts until 2020 for the Asia-Pacific markets of India, China, Australia and Japan. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of clinical trials including failure rates and pipeline analysis, and analysis of deals relevant to Ovarian Cancer (OC).
Platinum-based chemotherapy, predominantly the chemotherapy regimen paclitaxel and carboplatin, is the standard of care for the treatment of platinum-sensitive OC (both first-line and recurrent). The initial treatment is quite effective, with the majority of patients entering remission. However, almost all relapse, and after successive periods of remission and relapse either die or progress to platinum-resistant disease, for which the prognosis is poor. There is a clear gap in the market for maintenance therapies, as well as for more effective treatment options in platinum-resistant or refractory patients. Complete Report is Available @http://www.rnrmarketresearch.com/ovarian-cancer-therapeutics-in-asia-pacific-markets-to-2020-off-patent-chemo-regimens-to-retain-dominance-despite-new-launches-market-report.html .
Although the current developmental pipeline is quite crowded, efficacy with these late-stage drugs has been poor, at best demonstrating minimal improvements in progression-free survival, but not overall survival. The promising investigational drug candidates olaparib and trebananib are expected to gain approval during the forecast period. However, even on approval they are not expected to have a high market penetration, owing to their minimal therapeutic efficacy and anticipated premium prices. As a result, the OC market in APAC is expected not be driven by new drug approvals, but primarily by inflation, and the increase in the prevalence of OC. Market revenue is forecast to rise at a limited CAGR of 5.1% to $417.6m in 2020.
Despite the poor clinical performance of current late-stage pipeline drugs, there is evidence of continued interest in the OC market, with a high number of drug candidates in the initial developmental pipeline, particularly at the Preclinical phase. There is a wide range of novel molecular targets distributed among these drug candidates, including growth factors, serine/threonine protein kinases and tumor associated antigens. This suggests a continued interest in introducing more targeted therapies into the treatment of OC, the use of which in this indication lags significantly behind that in others in oncology. Order a Purchase copy of this report @http://www.rnrmarketresearch.com/contacts/purchase?rname=266266 . (This is a premium report priced at US$4995 for a single user License.)
The report analyzes treatment usage patterns, drug types available and pipeline and market forecasts for OC. It covers and includes: A brief introduction to OC, including the disease's pathogenesis, risk factors and diagnosis; In-depth analysis of the drug combinations used in the treatment of OC, including analyses of their safety, efficacy, and place in the disease treatment algorithm, as well as a heat map comparing the drug combinations in terms of safety and efficacy; A comprehensive review of the pipeline for OC therapies, including individual analysis of a number of late-stage pipeline drugs that have the potential to enter the market in the forecast period; the pipeline is analyzed on the basis of phase distribution, molecule type and molecular target, and route of administration; Additional in-depth analysis of pipeline drug clinical trials by phase, molecule type, trial size, and trial duration, and program failure rate analyses for each molecule type and mechanism of action; Multi-scenario forecast market data to 2020, taking into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs, and the changes in disease epidemiology across the APAC markets; Discussion of the drivers and barriers for market growth; In-depth analysis of licensing and co-development deals involving drugs indicated in OC, including an outline of the key deals. Inquire for Discount @http://www.rnrmarketresearch.com/contacts/discount?rname=266266. (This is a premium report priced at US$4995 for a single user License.)
Reasons to Buy
The report will assist business development and enable marketing executives to strategize their product launches, by allowing them to:
- Understand the efficacy and safety of the current monotherapies and drug combinations used in the treatment of OC, with in-depth analysis of the disease treatment algorithm
- Understand the key signaling pathways and molecular targets currently under investigation in OC drug development
- Understand the vast scope of the pipeline, including which molecule types and mechanisms of action are prominent
- Observe the trends in clinical trial duration and size among clinical phases and molecule types, and use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for OC therapeutics
- Assess the potential clinical and commercial impact of current late-stage pipeline molecules in the OC therapeutics market
Another research on Ovarian Cancer - Pipeline Review, H2 2014 provides comprehensive information on the therapeutic development for Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ovarian Cancer and special features on late-stage and discontinued projects.
A 2014 report on Cancer Immunotherapy: immune checkpoint inhibitors, cancer vaccines, and adoptive T-cell therapies focuses on the rising potential for the newest and most promising of cancer treatments: cancer immunotherapy. It focuses on the three principal types of therapeutics that have become the major focuses of research and development in cancer immunotherapy (which is often called "immuno-oncology") in recent years:
- Checkpoint inhibitors (discussed in Chapter 2)
- Therapeutic anticancer vaccines (discussed in Chapter 3)
- Adoptive cellular immunotherapy (discussed in Chapter 4)
The report also includes a survey on adoptive immunotherapy for cancer, which was conducted by a team of expert analysts in conjunction with this report, and is discussed in Chapter 5. Read more at http://www.rnrmarketresearch.com/cancer-immunotherapy-immune-checkpoint-inhibitors-cancer-vaccines-and-adoptive-t-cell-therapies-market-report.html .
Explore more reports on cancer therapeutics industry at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/cancer-therapeutics .
RnRMarketResearch.com is a digital library of 500,000+ syndicated market research reports and in-depth studies of 5000+ micro markets. We provide reports by 100+ publishers on a range of categories and industries.
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
Connect with Us:
G+ / Google Plus: https://plus.google.com/104156468549256253075/posts
RSS / Feeds: http://www.rnrmarketresearch.com/feed
SOURCE RnR Market Research